Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.40 |
| ▸ | PGK2 | P07205 | 1/20 | 0.40 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | EDNRA | P25101 | 3/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6589242 | 0.89 | SLC11A2 (0.35) | PGK1PGK2SLC11A2HTR1D | |
| SCHEMBL1823441 | 0.85 | ALDH1A1 (0.32) | PGK1PGK2GAAHTT | |
| SCHEMBL6588948 | 0.85 | ALDH1A1 (0.39) | PGK1PGK2SLC11A2GAAHTR1D | |
| SCHEMBL8793007 | 0.80 | MEN1 (0.38) | PGK1PGK2EDNRA | |
| SCHEMBL1022724 | 0.80 | ATM (0.38) | GAAHTR1D | |
| SCHEMBL6587785 | 0.78 | ALDH1A1 (0.37) | HTT | |
| SCHEMBL7982969 | 0.76 | CSNK2A1 (0.37) | GAAHTR1D | |
| SCHEMBL11860918 | 0.76 | CYP3A4 (0.41) | GAA | |
| SCHEMBL954302 | 0.76 | HTT (0.32) | GAAHTT | |
| SCHEMBL5728741 | 0.76 | CYP2A6 (0.33) | GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716215-B1 | CURABLE LIQUID COMPOSITIONS CONTAINING BISOXAZOLINE | HENKEL AG & CO KGAA (DE) | 2010-06-02 | — | — | EP | disclosed |
| EP-1716215-B1 | CURABLE LIQUID COMPOSITIONS CONTAINING BISOXAZOLINE | HENKEL AG & CO KGAA (DE) | 2010-06-02 | — | — | EP | disclosed |
| US-7390430-B2 | And 1,6-hexanediol diacrylate; curing to a thermosetting resin by zwitterionic polymerization, which does not require a curing agent; adhesives and encapsulants | NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390430-B2 | And 1,6-hexanediol diacrylate; curing to a thermosetting resin by zwitterionic polymerization, which does not require a curing agent; adhesives and encapsulants | NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390430-B2 | And 1,6-hexanediol diacrylate; curing to a thermosetting resin by zwitterionic polymerization, which does not require a curing agent; adhesives and encapsulants | NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) | 2008-06-24 | — | — | US | disclosed |
| US-20070032578-A1 | Curable liquid compositions containing bisoxazoline | HENKEL KGAA (DE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032578-A1 | Curable liquid compositions containing bisoxazoline | HENKEL KGAA (DE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032578-A1 | Curable liquid compositions containing bisoxazoline | HENKEL KGAA (DE) | 2007-02-08 | — | — | US | disclosed |
| EP-1716215-A1 | CURABLE LIQUID COMPOSITIONS CONTAINING BISOXAZOLINE | National Starch and Chemical Investment Holding Corporation (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005085384-A1 | CURABLE LIQUID COMPOSITIONS CONTAINING BISOXAZOLINE | NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING COPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
| EP-0946552-B1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | ENCYSIVE PHARMACEUTICALS INC (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20030208084-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. | 2003-11-06 | — | — | US | disclosed |
| US-6632829-B2 | Thienyl, furyl and pyrrolyl-sulfonamides, useful for treating hypertension, cardiovascular disease, asthma, pulmonary hypertension, inflammatory diseases, vision defects, menstrual disorders, renal failure and other diseases | TEXAS BIOTECHNOLOGY CORP. | 2003-10-14 | — | — | US | disclosed |
| EP-1342721-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. (US) | 2003-09-10 | — | — | EP | disclosed |
| US-6420567-B1 | PRODRUGS | TEXAS BIOTECHNOLOGY CORPORATION | 2002-07-16 | — | — | US | disclosed |
| US-20020091272-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030208084-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | EDNRA, EDNRB, ECE1 | PGK1 4298/4885PGK2 3641/4885SLC11A2 1069/4885 |
| US-20020091272-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | EDNRA, EDNRB, ECE1 | PGK1 4298/4885PGK2 3641/4885SLC11A2 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.